Amphastar Q1 revenue and adjusted EPS miss estimates

Amphastar Pharmaceuticals,

07/05/2026 21:54

Overview

US injectables maker's Q1 revenue was flat yr/yr and missed analyst expectations

Adjusted EPS for Q1 missed analyst expectations

Lower prices for key products and higher costs weighed on margins and profit

Outlook

Company did not provide specific financial guidance or outlook in the press release

Result Drivers

LOWER PRICES FOR KEY PRODUCTS - Company said lower average selling prices for BAQSIMI, glucagon, phytonadione, and epinephrine multi-dose vial reduced gross margin

PRODUCT MIX SHIFTS - BAQSIMI and glucagon sales declined due to lower prices and volumes, while other products and new launches contributed to revenue growth

HIGHER MANUFACTURING AND R&D COSTS - Increased manufacturing expenses from facility expansion and higher R&D spending, including a $2 mln licensing payment, weighed on profit

Company press release: ID:nACS9PqDQa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Miss
$171.17 mln
$173.39 mln (6 Analysts)
Q1 Adjusted EPS
Miss
$0.42
$0.71 (7 Analysts)
Q1 EPS
$0.14
Q1 Adjusted Net Income
Miss
$19.48 mln
$33.21 mln (6 Analysts)
Q1 Net Income
$6.42 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

Wall Street's median 12-month price target for Amphastar Pharmaceuticals, Inc is $28.00, about 17.2% above its May 6 closing price of $23.90

The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 7 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)